<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127564">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01664975</url>
  </required_header>
  <id_info>
    <org_study_id>hnslblzlzx2011-3</org_study_id>
    <nct_id>NCT01664975</nct_id>
  </id_info>
  <brief_title>Treatment of Peripheral T-cell Lymphoma</brief_title>
  <official_title>A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mingzhi Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of GDPT regiment
      (gemcitabine，cisplatin,Prednisone ,Thalidomide

      ) for patients with Peripheral T-cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot
      be treated successfully with the conventional chemotherapy of CHOP. The investigators have
      been proceeding this trial to evaluate the efficacy and safety of the combination
      chemotherapy regiment GDPT regiment (gemcitabine，cisplatin,Prednisone ,Thalidomide

      ) in the patients with Peripheral T-cell lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 24 months)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>every 6 weeks,up to completion of treatment(approximately 18 weeks )</time_frame>
    <safety_issue>No</safety_issue>
    <description>21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to the date of death (approximately 5 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median survival time</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>GDPT regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHOP regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDPT regimen</intervention_name>
    <description>GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.</description>
    <arm_group_label>GDPT regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP regimen</intervention_name>
    <description>CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.</description>
    <arm_group_label>CHOP regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time &gt; 3 months
        Histological confirmed Peripheral T cell lymphoma None of chemotherapy or radiotherapy has
        been previously used None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl,
        neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤
        1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L,
        serum plasminogen is normal (Inclusion Criteria of 1,3,6 groups ) At least one measurable
        lesion None of other serious diseases, cardiopulmonary function is normal Pregnancy test
        of women at reproductive age must be negative Patients could be followed up None of other
        relative treatments including the traditional Chinese medicine, immunotherapy,biotherapy
        except anti-bone metastasis therapy and other symptomatic treatments.

        volunteers who signed informed consent.

        Exclusion Criteria:

        Disagreement on blood sample collection Patients allergic of any of drug in this regimen
        or with metabolic disorder Pregnant or lactating women Serious medical illness likely to
        interfere with participation Serious infection Primitive or secondary tumors of central
        nervous system Chemotherapy or radiotherapy contraindication The evidence of CNS
        metastasis History of peripheral nervous disorder or dysphrenia patients participating in
        other clinical trials patients taking other antitumor drugs patients estimated to be
        unsuitable by investigato
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingzhi Zhang, Pro,Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingzhi zhang, Pro，Dr</last_name>
    <phone>13838565629</phone>
    <email>Mingzhi_zhang@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncology Department of The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, Pro,Dr</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 19, 2013</lastchanged_date>
  <firstreceived_date>August 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Mingzhi Zhang</investigator_full_name>
    <investigator_title>the director of oncology department of the first affiliated hospital</investigator_title>
  </responsible_party>
  <keyword>Peripheral T-cell lymphoma;chemotherapy;</keyword>
  <keyword>RR;PFS;OS</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
